Quality Assurance in Clinical Trials

Slides:



Advertisements
Similar presentations
The Role of the IRB An Institutional Review Board (IRB) is a review committee established to help protect the rights and welfare of human research subjects.
Advertisements

Managing Compliance Related to Human Subjects Research Review Joseph Sherwin, Ph.D. Office of Regulatory Affairs University of Pennsylvania Fourth Annual.
What FDA Looks for When Inspecting IRBs and Sponsors Marian J. Serge Nurse Consultant Division of Bioresearch Monitoring Office of Compliance Center for.
CROMS NIDCR Clinical Monitoring
Tips to a Successful Monitoring Visit
IRB Application Process Deb Schneider IRB Administrator Office of Research & Sponsored Programs 1055 AB (313)
The Principal Investigator’s Roles and Responsibilities Chicken Soup for the Busy Coordinator (May 2010)
What is a Data and Safety Monitoring Plan and how do I get one? Presented by Office of Human Research Protection.
Issue Identification, Tracking, Escalation, and Resolution.
Research Coordination Guidance The Committees on Human Research Serving University of Vermont & Fletcher Allen Health Care
Quality Management within the Clinical Research Process
Common Mistakes & Audits 05/21/2014. Summary of audit findings by category.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
UTHSC IRB Donna Hollaway, RN, CCRC 11/30/2011 Authority to Audit 45 CFR (e) An IRB shall conduct continuing review of research covered by this.
IRB Determinations 1. AAHRPP Site Visit Results Site visitors observed a real commitment to human subject protections Investigator and research staff.
Columbia University IRB IRB 101 September 21, 2005 George Gasparis, Executive Director, CU IRB Asst. V.P. and Sr. Asst. Dean for Research Ethics.
CUMC IRB Investigator Meeting Human Subjects Research Non-Compliance September 15, 2005.
Human Research Protection Program Training: Post-Approval Event Reporting March 26, 2008 Lisa Voss, MPH, CIP Assistant Director, QIU Human Research Protection.
Effective CAPA Program, a Valuable Tool in Quality Improvement Dharmi Trivedi.
Brookhaven Science Associates U.S. Department of Energy 1 Brookhaven National Laboratory Protocol Compliance Monitoring Darcy Mallon May 7, 2009.
Unlocking the Mystery of General Information Reporting Research Compliance Administration Training Presentation Wednesday, June 6, 2007 Presenter:Heather.
Incident Reporting Procedure
Continuing Review VA Requirements Kevin L. Nellis, M.S., M.T. (A.S.C.P.) Program Analyst Program for Research Integrity Development and Education (PRIDE)
Building Quality Assurance into Clinical Trials. Objectives for Today: Define Quality in Research Describe How to Initiate Corrective and Preventative.
Elements of Clinical Trial Quality Assurance Regulatory Coordinator –SCTR SUCCESS Center QA Monitor – NIDA Clinical Trials Network Stephanie Gentilin,
Device Clinical Trials and More… Michael E. Marcarelli, PharmD Director, Division of Bioresearch Monitoring Office of Compliance Center for Devices and.
EMORY INSTITUTIONAL REVIEW BOARD VERSION Unanticipated Problems, Protocol Deviations and Non-Compliance.
RESCUE: ACRIN 4701 Protocol Development & Regulatory Compliance (PDRC) Josephine Schloesser, ACRIN Monitor Chris Steward, ACRIN QC Auditor.
Joint Research & Enterprise Office Training The team, the procedures, the monitor and the Sponsor Lucy H H Parker Clinical Research Governance Manager.
1. Objectives  Describe the responsibilities and procedures for reporting and investigating ◦ incidents / near-miss incidents ◦ spills, releases, ◦ injuries,
Michelle Groy Johnson Quality Improvement Officer Research Integrity Office Tough Love: Understanding the Purpose and Processes of Quality Assurance.
University of Miami Office of Research Compliance Assessment Lynn E. Smith, JD, CIM, CIP Johanna Stamates, RN, BA, CCRC With assistance from Elizabeth.
Monitoring IRB Monitoring of Clinical Trials. Types of Monitoring Internally Internally Externally Externally.
Research Studies GOTCHA’S By Sally Duffy. Failure to follow protocol, investigator agreements and regulations Did not use device/drug in manner specified.
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
UC DAVIS OFFICE OF RESEARCH Overview of Good Clinical Practices (GCP) Investigator and Study Team Responsibilities Miles McFann IRB Administration Training.
ISO NON-CONFORMANCE, CORRECTIVE AND PREVENTIVE ACTION.
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
Investigational Devices and Humanitarian Use Devices June 2007.
RIHES-II: H ANDLING A UDITS AND I NSPECTIONS E FFECTIVE D ATE 25 D ECEMBER 2006 V ERSION : 3.0 บุญเหลือ พรึงลำภู 15 มกราคม 2557.
Office of Human Research Protection Georgia Health Sciences University.
ACRIN CV Committee ACRIN PDRC ACRIN PA 4008 Protocol and Regulatory Requirements Patricia Atkinson, Quality Control Monitor.
CONDUCTING COMPLIANCE ASSESSMENTS Allen Ditch Director Corporate Quality Bristol Myers Squibb Medical Research Summit March 6, 2003.
Responsibilities of Sponsor, Investigator and Monitor
Issues that Matter Notification and Escalation
Good Clinical Practice (GCP) and Monitoring Practices
Risk Assessment Beginning an Analysis Date by Jim Bowman.
Lisa Hoebelheinrich, JD, CHRC Associate Vice Chancellor, Compliance
Governing Body QAPI 2013 Update for ASC
Incident Reporting And Investigation Program
Responsibilities of Sponsor, Investigator and Monitor
Implementing a Successful Corrective and Preventative Action Program
Reportable Events Emory IRB 9/11/2014.
IRB reporting updates.
What is a Data and Safety Monitoring Plan and how do I get one?
Amendments A how-to Prepared by: Christine Melton-Lopez, IRB Associate.
Reportable Events & Other IRB Updates February 2017
FMEA.
Lucrecia Johnson MSW, LSW Mary Bartlett MSW, LISW-S
ClinicalTrials.gov PRS – How to Register and Maintain a Record
Director, Quality and Accreditation
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
Navigating Non-Compliance
Incident Reporting And Investigation Program
Monitoring, Auditing and Compliance
Event Reporting in Human Subjects Research
Understanding the Process of Documenting Informed Consent
CTSA27 So you want COMIRB to be your sIRB: What you need to know.
Katherine Hawthorne, BS, rn, CCRP Program Manager
Presentation transcript:

Quality Assurance in Clinical Trials Stephanie deRijke Clinical Trials Audit and Compliance

Objectives Discuss the importance of quality assurance in clinical research Describe regulatory impact of monitoring and how to respond to monitoring reports Outline the steps to take when a problem occurs Detail the processes of root cause analysis and corrective and preventive actions

Quality Assurance: what QA is the process by which sponsors and researchers monitor and evaluate the protocol implementation. QA prevents patterns of error QA leads to reliable research data

Quality Assurance: how Sponsor monitoring Self-monitoring Self-checks Standard tools Written procedures

Monitoring process Site initiation visit Centralized monitoring Periodic site monitoring Close-out

Reports Ask monitor to send you a written report Verify findings Use report as a to-do list Write on report as you resolve things Consider the IRB’s reporting requirements Review with PI; PI should sign if possible

Tips on reviewing reports First look for anything awful Look for ongoing or pending items that weren’t resolved after the previous visit Look for things they ask you to report to IRB “Report to IRB” vs “Report per IRB policies” Look for hidden attachments or appendices

Responding to monitoring findings If findings are wrong, provide documentation to monitor and ask for a revised letter or at least keep documentation of correspondence Report items to IRB if monitor asks If something does not need to be reported to IRB, respond to the monitor that you don’t plan to report and provide them with IRB P&P If there becomes a pattern of problems, respond with a CAPA

Self-monitoring Emory University Self-Monitoring Tool www.ctac.emory.edu Review a minimum of twice per year More for high risk or high enrolling studies Consider reporting requirements of sponsor and IRB

Problems in Research Steps to resolve problems Identify problems Make immediate corrections Evaluate risk Identify root cause of each problem Identify corrective and preventive action for each root cause

Problem Statement A problem statement should include Description of the problem Where and when it happened Weight of the problem Requirements that were not met Evidence to show that requirements weren’t met

Corrections “Immediate corrections” include Evaluating rights, welfare, and safety of subject Reporting, if applicable: subject, subject’s family, sponsor, and/or IRB

Evaluate Risk

Risk Severity Frequency If Risk is there, move to RCA and CAPA Rights, welfare, and safety of current and future subjects Frequency Systematic problem Protocol design Departmental, local problem If Risk is there, move to RCA and CAPA

Immediate Corrections Problem Occurs Immediate Corrections Assess Risk No risk Yes risk Root Cause Analysis CAPA Plan If CAPA didn’t resolve root cause Effectiveness Check

Root Cause The root cause is the initiating, most basic cause of a problem that may or may not lead to a chain of causes or other problems (domino effect) Eliminating the root cause should prevent recurrence of the problem

Root Cause Analysis (RCA) The RCA is the process of identifying the root cause and the downstream effect on the causal chain Since noncompliance is usually from a system failure, not a person failure, RCA should focus on identifying underlying problems that contribute to error rather than focusing on mistakes made by individuals

RCA Steps Questions to ask Why and how did the problem occur? What were the steps? Who was impacted by the problem? Keep asking “why” and “how” until you reach the root cause

Documenting the RCA Summarize the problem or event Note the sequence of events Note the implicated processes Summarize the immediate corrections taken Summarize the root cause investigation

Corrections vs Corrective Actions Immediate actions taken to resolve a problem before the root cause is known Putting out fires Could resolve minor deviations/noncompliance Corrective Actions If risk of problem (severity and frequency) is greater, do RCA and move to CAPA Process

What is CAPA? Corrective and Preventive Actions Corrective Actions The process of reacting to an existing problem and fixing it Preventive Actions The process of detecting potential problems and eliminating them

FDA Warning Letter Excerpts “You failed to secure the investigator’s compliance and allowed subjects to be put at risk for potential adverse effects, such as…Your response is inadequate in that it does not describe your corrective and preventive actions in sufficient detail.” “You stated that study subjects will be re-consented with a revised consent form after it is approved by the IRB. Your response is inadequate as it lacks a corrective and preventive action plan to ensure that adequate consent forms are provided to study subjects prior to any study related procedures in the future.”

CAPA Don’ts! We will retrain the study team… Study team members have been terminated or will be reassigned… We will have 5 people check…. Don’t overpromise with detailed CAPA plans that we can’t maintain

CAPA Musts! Corrective: Assess and correct safety/rights/welfare of subjects. Report to subjects, IRB, sponsor, and/or internal department. Document corrections. Preventive: Develop and document a process, train on the process, implement the process, evaluate the process, amend process as necessary.

“SMART” CAPAs

Effectiveness Check Build in an effectiveness check as the final step of CAPA Effectiveness checks verify that the CAPAs resolved the root cause

Documenting the CAPA Action type (corrective or preventive) Action description Owner Due date Plan for effectiveness check Effectiveness check outcome

In Summary Problem occurs Immediate corrections taken Determine impact of problem and risk of recurrence (risk = severity + frequency) Root cause analysis CAPA plan Effectiveness check

CTAC Website

Contacts Stephanie deRijke Emory University Clinical Trials Audit and Compliance www.ctac.emory.edu smickle@emory.edu (404) 712-5159